Fig. 1: Identification of lestaurtinib as a novel inhibitor of therapy-sensitive and -resistant ovarian cancer cells. | npj Precision Oncology

Fig. 1: Identification of lestaurtinib as a novel inhibitor of therapy-sensitive and -resistant ovarian cancer cells.

From: Lestaurtinib’s antineoplastic activity converges on JAK/STAT signaling to inhibit treatment naïve and therapy resistant forms ovarian cancer

Fig. 1

a Viability of indicated cell lines following 48 h of treatment with 1 µM of the 145 compounds contained in the Cayman Chemical epigenetic drug library (#11076) relative to DMSO vehicle. N = 2. b Drug screen hit prioritization schema. Figure created with BioRender.com. c Dose response curves (two-fold dilution starting at 2.5 µM) and IC50 concentrations for lestaurtinib in a panel of therapy-sensitive and -resistant ovarian cancer cell lines following 5–10 days of treatment. N = 8. Graphs represent mean ± standard error. Abbreviations: Cis Res cisplatin-resistant, OlapR olaparib-resistant.

Back to article page